Close

BioLineRx (BLRX) Approved to Evaluate BL-8040 as CML Treatment in Phase 1/2 by SMC Director

April 10, 2014 7:04 AM EDT Send to a Friend
BioLineRx (Nasdaq: BLRX) announced that Prof. Arnon Nagler, Director of the Hematology Division and Bone Marrow Transplantation Center at Sheba ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login